Please use this identifier to cite or link to this item:
http://hdl.handle.net/1942/2374
Title: | Alendronate produces greater effects than raloxifene on bone density and bone turnover in postmenopausal women with low bone density: results of EFFECT (EFficacy of FOSAMAX (R) versus EVISTA (R) Comparison Trial) International | Authors: | Sambrook, PN GEUSENS, Piet Ribot, C Solimano, JA Ferrer-Barriendos, J Gaines, K Verbruggen, N Melton, ME |
Issue Date: | 2004 | Publisher: | BLACKWELL PUBLISHING LTD | Source: | JOURNAL OF INTERNAL MEDICINE, 255(4). p. 503-511 | Abstract: | Objectives. Alendronate and raloxifene are antiresorptive agents with different mechanisms of action, each used to treat osteoporosis in postmenopausal women. This study was undertaken to compare the efficacy and tolerability of alendronate to raloxifene in postmenopausal women with low-bone density. Design. Randomized, double-masked, double-dummy multicentre international study. Setting. Clinical trial centres in Europe, South America and Asia-Pacific. Subjects. A total of 487 postmenopausal women with low bone density, based on bone mineral density (BMD) of the lumbar spine or hip (T-score less than or equal to-2.0). Interventions. Patients received either alendronate 70 mg once weekly and daily placebo identical to raloxifene or raloxifene 60 mg daily and weekly placebo identical to alendronate for 12 months. Main outcome measures. Evaluations included BMD of the lumbar spine and hip and markers of bone turnover at 6 and 12 months and adverse event reporting. Results. Alendronate demonstrated substantially greater increases in BMD than raloxifene at both lumbar spine and hip sites at 12 months. Lumbar spine BMD increased 4.8% with alendronate vs. 2.2% with raloxifene (P < 0.001). The increase in total hip BMD was 2.3% with alendronate vs. 0.8% with raloxifene (P < 0.001). Reductions in bone turnover were significantly larger with alendronate than raloxifene. Overall tolerability was similar, however, the proportion of patients reporting vasomotor events was significantly higher with raloxifene (9.5%) than with alendronate (3.7%, P = 0.010). The proportion of patients reporting gastrointestinal events was similar between groups. Conclusion. In postmenopausal women with low bone density, improvements in BMD and markers of bone turnover were substantially greater during treatment with alendronate compared to raloxifene. | Notes: | Univ Sydney, Sydney, NSW 2006, Australia. Univ Campus Limburg, Biomed Onderzoeksinst, Diepenbeek, Belgium. Univ Hosp, Dept Rheumatol, Maastricht, Netherlands. CHU Toulouse, Hop Rangueil, Toulouse, France. Inst Med Miraflores, Lima, Peru. Hosp Univ Cent Asturias, Oviedo, Spain. Merck & Co Inc, Whitehouse Stn, NJ USA.Sambrook, PN, Univ Sydney, Royal N Shore Hosp, Inst Bone & Joint Res, Level 4,Block 4,Pacific Highway, St Leonards, NSW 2065, Australia.sambrook@med.usyd.edu.au | Keywords: | alendronate; bisphosphonates; postmenopausal osteoporosis; raloxifene; selective oestrogen receptor modulators | Document URI: | http://hdl.handle.net/1942/2374 | ISSN: | 0954-6820 | e-ISSN: | 1365-2796 | DOI: | 10.1111/j.1365-2796.2004.01317.x | ISI #: | 000220357200009 | Category: | A1 | Type: | Journal Contribution | Validations: | ecoom 2005 |
Appears in Collections: | Research publications |
Show full item record
SCOPUSTM
Citations
76
checked on Sep 5, 2020
WEB OF SCIENCETM
Citations
72
checked on Sep 20, 2024
Page view(s)
62
checked on Jul 28, 2023
Google ScholarTM
Check
Altmetric
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.